ESTRO 2021 Abstract Book

S1209

ESTRO 2021

Conclusion A genetic test could be an opportunity because generate knowledge and give patients a dynamic role in the decision-making approach even if it carries a huge burden of emotions. Prediction of single patient radiosensitivity before treatement could help drawing a more and more tailored RT in the era of personalized approach.

Digital Poster: Communication

PO-1475 Systematic prospective data mining in everyday practice – the NHS approach for proton beam therapy E.J. Hwang 1,2 , N. Burnet 3,1 , A. Crellin 4 , V. Ahern 5,6 , D. Thwaites 2,7 , S. Gaito 8 , Y. Chang 9 , E. Smith 1,3,8 1 The Christie NHS Foundation Trust, Proton Beam Therapy, Manchester, United Kingdom; 2 University of Sydney, School of Physics, Sydney, Australia; 3 University of Manchester, Manchester Cancer Research Centre, Manchester, United Kingdom; 4 NHS England, National Clinical Lead Proton Beam Therapy, England, United Kingdom; 5 Sydney West Radiation Oncology Network, Radiation Oncology, Sydney, Australia; 6 University of Sydney, Westmead Clinical School Faculty of Medicine and Health, Sydney, Australia; 7 Leeds University, Medical physics, Leeds Institute of Cancer and Pathology, Leeds, United Kingdom; 8 The Christie NHS Foundation Trust, Proton Clinical Outcomes Unit, Manchester, United Kingdom; 9 University College London Hospital NHS Foundation Trust, Clinical Oncology, London, United Kingdom Purpose or Objective The rationale for proton beam therapy (PBT) use combines reduced toxicity and potential dose escalation, as supported by dosimetric studies comparing PBT with photon radiotherapy. However, questions remain of whether, and by how much, this leads to clinical benefit for patients. Whilst awaiting results from appropriately powered randomised trials, and to supplement those, alternative complementary research methodologies can strengthen the evidence base. This report aims to detail the approach taken by the first United Kingdom (UK) National Health Service (NHS)- funded high-energy PBT centre at The Christie NHS Foundation Trust in Manchester to evaluate PBT by utilising each patient’s detailed data, ensuring that ‘every patient counts’. Materials and Methods The challenges with PBT data generation, collection and analysis are described, as well as the different approaches taken by jurisdictions internationally to address these challenges, including the European Particle Therapy Network (EPTN) and the Pediatric Proton/Photon Consortium Registry (PPCR). The rationale for the strong emphasis on outcomes data collection by the NHS with the establishment of the Proton Clinical Outcomes Unit (PCOU) which collects, curates and analyses PBT outcomes data prospectively for Christie- treated patients and retrospectively for UK patients treated overseas, is outlined in detail. The PCOU’s unique features in regard to its digital solution, its integration of patient-reported outcomes and its novel relationship with clinical trials and evaluative commissioning are highlighted. Results The Christie electronic patient record was developed as a versatile platform for ‘outcomes tracking’ as well as clinical care. A number of electronic eForms were developed for comprehensive data capture, using data tree and conditional logic approaches, where answers prompt further questions specific to tumour site and patient